OncoGenex' OGX-011 meets endpoint in Ph II cancer study
OncoGenex Technologies, a Canada-based, clinical-stage biotechnology company, says that its lead product candidate, custirsen (OGX-011) improved survival duration when combined with second-line chemotherapy in patients with hormone refractory prostate cancer. The findings, which are from a Phase II study, were presented at this year's Genitourinary Cancers Symposium in San Francisco, USA.
The drug, which is being co-developed by OncoGenex with US firm Isis Pharmaceuticals (Marketletters passim), is designed to block the production of the cell-survival protein clusterin, which is over-expressed in several cancer indications and in response to certain cancer therapies. Increased clusterin production is linked with more rapid disease progression, increased resistance and reduced overall survival.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze